Myeloproliferative Neoplasms

David S. Snyder, MD, details mutations and discusses investigational treatments within the field of myeloproliferative neoplasms.

David S. Snyder, MD, associate chair and professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, discusses the use of ruxolitinib (Jakafi) in myelofibrosis.

Jeanne M. Palmer, MD, discusses the current treatment landscape for patients with polycythemia vera and highlighted the impact that ruxolitinib has had on the second-line treatment setting.

Srdan Verstovsek, MD, PhD, discusses the rationale for targeting JAK signaling, new drugs under study for this pathway, and clinical challenges associated with these therapies.

Dysregulation of the JAK pathway plays a role in the development of numerous tumor types; it is particularly central to the pathophysiology of myelofibrosis and has long been recognized as a potentially valuable therapeutic target in that malignancy.

Two-year findings from the follow-up phase III CONTI-PV randomized trial showed that ropeginterferon alfa-2b, a novel pegylated formulation of interferon alfa-2b, reached a significantly higher rate of complete hematologic response versus hydroxyurea in patients with polycythemia vera.